371 related articles for article (PubMed ID: 19178933)
41. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Rebbeck TR; Kauff ND; Domchek SM
J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
[TBL] [Abstract][Full Text] [Related]
42. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
43. Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: women at high risk for breast-ovarian cancer.
Shochat T; Dagan E
J Sleep Res; 2010 Jun; 19(2):333-40. PubMed ID: 20337906
[TBL] [Abstract][Full Text] [Related]
44. A survey of preventive measures among BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
[TBL] [Abstract][Full Text] [Related]
45. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
Esplen MJ; Hunter J; Leszcz M; Warner E; Narod S; Metcalfe K; Glendon G; Butler K; Liede A; Young MA; Kieffer S; DiProspero L; Irwin E; Wong J
Cancer; 2004 Nov; 101(10):2327-40. PubMed ID: 15478194
[TBL] [Abstract][Full Text] [Related]
46. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
47. Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery.
Awtrey CS; Abu-Rustum NR; Disa JJ; Ivy JJ; Kauff ND; Hummer AJ; Barakat RR
Gynecol Oncol; 2005 Dec; 99(3):720-5. PubMed ID: 16169063
[TBL] [Abstract][Full Text] [Related]
48. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
[TBL] [Abstract][Full Text] [Related]
49. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
50. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
51. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Madalinska JB; Hollenstein J; Bleiker E; van Beurden M; Valdimarsdottir HB; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2005 Oct; 23(28):6890-8. PubMed ID: 16129845
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
53. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
54. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
[TBL] [Abstract][Full Text] [Related]
55. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
[TBL] [Abstract][Full Text] [Related]
56. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
[TBL] [Abstract][Full Text] [Related]
57. [Familial history of ovarian carcinoma: policy].
de Hullu JA; Kets CM; Massuger LF; Ligtenberg ML; van Ham MA; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2011; 155():A2392. PubMed ID: 21262027
[TBL] [Abstract][Full Text] [Related]
58. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
59. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
60. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
Johansen N; Liavaag AH; Tanbo TG; Dahl AA; Pripp AH; Michelsen TM
Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
